Research Article
Potential Therapeutic Benefit of Combining Gefitinib and Tamoxifen for Treating Advanced Lung Adenocarcinoma
Table 1
Clinical characteristics of study population.
| Characteristic | Number of patients | % |
| Age | | | >60 | 35 | 63% | ≦60 | 20 | 37% | Sex | | | Male | 25 | 45% | Female | 30 | 55% | Smoking history | | | Current smoker | 6 | 11% | Ever smoker habit | 17 | 31% | Never | 32 | 58% | Stage | | | IIIa | 2 | 4% | IIIb | 9 | 16% | IV | 44 | 80% | Tumor differentiation | | | Moderate | 36 | 65% | Poor | 19 | 35% | TTF1 | | | Positive | 45 | 82% | Negative | 10 | 18% | EGFR | | | Exon 19 deletion | 10 | 18% | L858 mutation | 14 | 26% | Unfound | 31 | 56% | ER- nuclear expression | | | Strong (≧6) | 38 | 69% | Weak | 17 | 31% | ER- cytosolic expression | | | Strong (≧6) | 27 | 49% | Weak | 28 | 51% | ER- nuclear expression | | | Strong (≧6) | 39 | 71% | Weak | 16 | 29% | ER- cytosolic expression | | | Strong (≧6) | 21 | 38% | Weak | 34 | 62% | Total | 55 | |
|
|